Overview

Anti-inflmmation Treatment in Mood Disorder and Deep Learning Prediction Model

Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This three-year study will enroll 180 patients with mood disorders (90 patients with major depressive disorder and 90 patients with bipolar disorder) and high pro-inflammatory cytokine levels. They will be randomly assigned to three groups of aspirin, statin and control groups for 12 weeks according to the disease group. The first aim of the study is to compare the efficacy of aspirin and statin in mood disorders. The second aim is to establish a gene-immuno-brain imaging treatment prediction model by deep learning technology, using pretreatment cytokines, neurocognitive function, brain structural/functional connectivity, and telomere length as the predictors.
Phase:
Phase 4
Details
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Treatments:
Aspirin
Atorvastatin